Nattokinase vs Telmisartan
A side-by-side research comparison of Nattokinase and Telmisartan across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Nattokinase | Telmisartan |
|---|---|---|
| Full name | Nattokinase (Subtilisin NAT) | Telmisartan (ARB / Partial PPAR-gamma Agonist) |
| Category | Cardiovascular | Cardiovascular |
| Status | Dietary supplement | FDA-approved drug |
| Mechanism | Directly degrades fibrin in blood clots via proteolytic activity. Also activates endogenous tissue plasminogen activator (tPA) and suppresses plasminogen activator inhibitor-1 (PAI-1), enhancing the body's own fibrinolytic system. | Blocks the angiotensin II type 1 (AT1) receptor to lower blood pressure and reduce vascular inflammation, while also acting as a partial PPAR-gamma agonist that improves insulin sensitivity, lipid handling, and mitochondrial biogenesis. |
| Molecular weight | ~27,728 Da | 514.62 Da |
| Half-life | ~8-12 hours (fibrinolytic activity) | ~24 hours |
| Bioavailability | Oral absorption confirmed; survives GI tract | ~42-58% oral |
| Typical dose | 2000-4000 FU (fibrinolytic units) | 20-80 mg per day |
| Frequency | Daily on empty stomach | Once daily |
| Route | Oral capsule | Oral tablet |
Nattokinase reported benefits
- Fibrin clot dissolution
- Blood pressure reduction
- Improved blood viscosity
- Reduced DVT risk
- Atherosclerosis prevention
- Natural anticoagulant alternative
Telmisartan reported benefits
- Blood pressure control
- PPAR-gamma metabolic benefits
- Improved insulin sensitivity
- Vascular anti-inflammatory effects
- Cardio- and reno-protection
- 24-hour coverage
Related comparisons
Research and educational reference only. Not medical advice.